analyst coverage rule

Below is a list of individual analysts that we are aware of that currently follow Synthetic Biologics.

Please note, that any opinions, estimates or forecasts regarding performance made by these analysts do not represent Synthetic Biologics or its management team.  Synthetic Biologics is under no obligation to update this list, thus it may not be complete or up to date.

Timothy Chiang


Keith A. Markey, Ph.D.

Griffin Securities

Andrew Fein

H.C. Wainwright & Co.

Adnan Butt

RBC Capital Markets

Y. Katherine Xu, Ph.D.

William Blair & Company